SUMMARY Since cefoxitin has been shown to be an effective alternative to spectinomycin for the treatment of infections due to penicillinase-producing strains of Neisseria gonorrhoeae (PPNG) its efficacy was compared with that of a new cephalosporin, ceftriaxone (R013-9904). One hundred and twenty eight men with culture-confirmed gonococcal urethritis were treated with either 250 mg of ceftriaxone intramuscularly or 2 g of cefoxitin intramuscularly with oral probenecid 1 g. The incidence of penicillin-resistant strains in each group was about 60%. Ceftriaxone was completely effective in treating both penicillin-sensitive and penicillin-resistant gonococcal urethritis. No side effects were noted. Ceftriaxone thus seems to be an effective and safe alternative to either spectinomycin or cefoxitin in the treatment of penicillin-resistant gonococcal urethritis.
Introduction
Since the first reported cases of infection with penicillinase-producing strains of Neisseria gonorrhoeae (PPNG) in 1976' 2 the world wide prevalence of these strains has increased.3 PPNG are widely distributed but so far are not a major problem in the United States. In many areas of the Far East, however, 30-607o of N gonorrhoeae isolates produce P-lactamase and are resistant to penicillin. 4 The standard treatment for gonorrhoea in US Navy personnel stationed in the Far East is presently with spectinomycin.5 With the recent report of a case of gonococcal urethritis due to a strain of bacteria resistant to both spectinomycin and penicillin6 a diminution of the efficacy of spectinomycin in treating PPNG becomes a serious possibility. Thus alternative treatment regimens for treating infections due to penicillin-resistant strains of gonococci must continue to be evaluated.
Ceftriaxone is a third generation cephalosporin with three properties that suggest efficacy in treating gonococcal urethritis caused by PPNG: (a) resistance to the TEM P lactamase produced by PPNG7; ( The cumulative percentage of isolates (both PPNG and non-PPNG) sensitive to increasing concentrations of ceftriaxone and cefoxitin is shown in table II. All isolates of N gonorrhoeae were sensitive to <0 03 1g/ml of ceftriaxone. The PPNG strains were slightly more susceptibile to ceftriaxone, but this difference was not statistically significant. The geometric mean minimum inhibitory concentration for penicillin-resistant isolates was 0-42 jg/ml for cefoxitin and 0 003 lAg/ml for ceftriaxone, while for penicillin-sensitive isolates these values were 0 59 Ag/ml and 0 004 Ag/ml respectively.
All patients treated with ceftriaxone reported minimal or no pain at the injection site. Several volunteered that ceftriaxone was the least painful injection that they had received for gonorrhoea. In contrast, several patients receiving cefoxitin had felt moderate or severe pain lasting up to several hours. No serious adverse effects were directly attributable to either ceftriaxone or cefoxitin. 
Discussion
In this study men with uncomplicated gonococcal urethritis were treated with either ceftriaxone or cefoxitin. Both antibiotics were highly effective against both penicillin-sensitive and penicillinresistant strains of N gonorrhoeae. This is the first evaluation of the use of ceftriaxone in an area where PPNG is highly endemic. As predicted by in vitro sensitivity testing and other workers' clinical experience, ceftriaxone was extremely effective and well tolerated in these patients. In this study strains of gonococci were associatedc with a pronounced prevalence of both chromosomal and plasmidmediated resistance to penicillin. 
